申请人:Glaxo Group Limited
公开号:US05618827A1
公开(公告)日:1997-04-08
Substituted phenylcarbamates and ureas of formula (I) ##STR1## wherein R.sup.1 represents a hydrogen or a halogen atom, or a C.sub.1-6 alkyl, C.sub.1-6 alkoxy or hydroxy group; R.sup.2 represents an oxadiazole or thiadiazole ring substituted by a group selected from C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, --CH.sub.2 C.sub.2-5 alkenyl, --CH.sub.2 C.sub.2-5 alkynyl, phenyl or benzyl; X represents NH or an oxygen atom; m represents zero, 1 or 2; R.sup.3 represents C.sub.1-6 alkyl, benzyl, --(CH.sub.2).sub.n R.sup.4 or ##STR2## R.sup.4 represents a group selected from cyano, hydroxyl, C.sub.1-6 alkoxy, phenoxy, C(O)C.sub.1-6 alkyl, C(O)C.sub.6 H.sub.5, --CONR.sup.6 R.sup.7, --NR.sup.6 COR.sup.7, --SO.sub.2 NR.sup.6 R.sup.7 or --NR.sup.6 SO.sub.2 R.sup.7 (wherein each of R.sup.6 and R.sup.7 independently represent a hydrogen atom, a C.sub.1-6 alkyl or phenyl group); n represents 2 or 3; R.sup.5 represents COR.sup.8 or SO.sub.2 R.sup.8 (wherein R.sup.8 represents a hydrogen atom, a C.sub.1-6 alkyl or phenyl group); and quaternary ammonium derivatives, piperidine N-oxides and pharmaceutically acceptable salts and solvates thereof; which compounds are potent and specific antagonists of 5-hydroxytryptamine (5HT; serotonin).
公式(I)的取代苯基氨基甲酸酯和脲类化合物
其中,R1代表氢原子、卤素原子或C1-6烷基、C1-6烷氧基或羟基;R2代表被选自C1-6烷基、C3-7环烷基、-CH2C2-5烯基、-CH2C2-5炔基、苯基或苄基的基取代的噁二唑或噻二唑环;X代表NH或氧原子;m代表零、1或2;R3代表C1-6烷基、苄基、-(CH2)nR4或的基式;
R4代表被选自氰基、羟基、C1-6烷氧基、苯氧基、C(O)C1-6烷基、C(O)C6H5、-CONR6R7、-NR6COR7、-SO2NR6R7或-NR6SO2R7(其中R6和R7各自独立地代表氢原子、C1-6烷基或苯基);
n代表2或3;R5代表COR8或SO2R8(其中R8代表氢原子、C1-6烷基或苯基);以及季铵衍生物、哌啶N-氧化物和药学上可接受的盐和溶剂;这些化合物是5-羟色胺(5HT;血清素)的有效和特异性拮抗剂。